Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Medical Oncology

Biology and Genetics: Decoding Your Reports

At a Glance

Pancreatic cancer reports combine pathology and genetic testing: pathology identifies the tumor subtype and features such as differentiation, margins, and lymph nodes, while germline and tumor testing can reveal inherited risks and treatment targets. Results such as BRCA, MSI-H, BRAF, or NTRK may guide care in specific situations.

When you are diagnosed with pancreatic cancer, your medical team uses two main “blueprints” to guide your treatment: the pathology report, which describes what the cells look like under a microscope, and the genetic/molecular report, which identifies the “engine” driving the cancer’s growth. Understanding these documents empowers you to ask about targeted treatments that might not be available for every patient.

Subtypes: PDAC vs. PACC

While most pancreatic cancers are Ductal Adenocarcinoma (PDAC), about 1% to 2% are Acinar Cell Carcinoma (PACC) [1][2]. These two types are biologically different and often require different treatment strategies.

  • PDAC (Ductal): Typically starts in the ducts. It is characterized by a thick, scarred environment called the stroma and almost always (about 90%) has a mutation in the KRAS gene [3][4].
  • PACC (Acinar): Starts in the enzyme-producing cells. These tumors are often larger and “softer” (less stroma) [1][5]. They are much less likely to have KRAS mutations but are significantly more likely to have mutations in DNA-repair genes like BRCA2 [6][7].

Reading Your Pathology Report

A high-quality diagnosis usually begins with an EUS-guided biopsy, where a gastroenterologist uses an ultrasound-equipped scope to take a precise tissue sample [8][9]. Your report should include several key terms:

  • Differentiation: This describes how much the cancer cells look like healthy cells. Well-differentiated cells look more “normal” and may grow more slowly, while poorly-differentiated cells look very disorganized and are often more aggressive [10].
  • Margins: If you have had surgery, this tells you if the surgeon was able to remove all the cancer. An R0 margin means no cancer cells were found at the edge of the tissue removed [11][12].
  • Lymph Nodes: The report will state how many nodes were removed and how many contained cancer (e.g., “2/15 nodes positive”) [13][12].

The Two Types of Genetic Testing

Current guidelines recommend that every person diagnosed with pancreatic ductal adenocarcinoma receive two distinct types of testing [14][15].

1. Germline Testing (Inherited Risk)

This tests the DNA you were born with (usually via a blood or saliva sample). It checks for inherited mutations you might have gotten from your parents, such as BRCA1/2, PALB2, or ATM [15][16]. This is vital for two reasons:

  • Treatment: If you have a BRCA mutation and your disease is metastatic, you may be a candidate for maintenance therapy with a PARP inhibitor (like olaparib) if your disease has not progressed after initial platinum-based chemotherapy [17][18].
  • Family: It identifies if your children or siblings need special cascade screening for their own cancer risk [15].

2. Somatic/Tumor Profiling (The “Engine”)

This tests the DNA of the tumor itself. Because tumors accumulate new mutations as they grow, this report may find “actionable” targets that aren’t in your blood [14][19]. A clinically appropriate comprehensive panel is recommended, particularly for advanced disease.

  • MSI-H/dMMR: A rare finding (about 1% of cases) that may make the cancer highly responsive to immunotherapy in an unresectable or metastatic setting [20][21].
  • BRAF and NTRK: Alterations like BRAF V600E mutations or NTRK fusions are extremely rare but “switchable” targets that can be treated with specific targeted drugs [22][23].

Completeness Checklist

Ensure your records include these specific details. If anything is missing, ask your oncologist to order the necessary “reflex” testing.

Category Must-Have Information
Pathology Specific subtype (PDAC, PACC, or Mixed), Differentiation grade, and (if surgical) Margin status and Lymph node count [24][11].
Germline Testing for BRCA1, BRCA2, PALB2, ATM, and Lynch Syndrome genes (MLH1, MSH2, etc.) [15][25].
Molecular Comprehensive panel including KRAS status, MSI/dMMR status, BRAF, and “fusion” testing (NTRK) [14][22].
Interpretation A clear distinction between “Pathogenic” (harmful) mutations and “Variants of Uncertain Significance” (VUS) [26]. A VUS must not guide treatment, preventive surgery, or predictive testing of relatives.

Common questions in this guide

How are PDAC and PACC different?
PDAC begins in the ducts of the pancreas and is the most common exocrine pancreatic cancer; KRAS changes are common. PACC begins in enzyme-producing cells, is less likely to have KRAS changes, and more often has DNA-repair changes such as BRCA2, so treatment planning can differ.
What should be included in a pancreatic cancer pathology report?
The report should identify whether the tumor is PDAC, PACC, or a mixed type and describe differentiation, which indicates how closely the cells resemble healthy tissue. After surgery, it should also record whether the margins are clear and how many lymph nodes contain cancer. A clear, or R0, margin means no cancer cells were seen at the edge of the removed tissue.
What is the difference between germline and tumor testing?
Germline testing uses blood or saliva to look for inherited DNA changes present throughout the body. Somatic or tumor profiling examines DNA changes in cancer cells that may have developed as the tumor grew; either result can affect treatment, while germline findings can also matter for relatives.
Why is germline testing recommended for people with PDAC?
It can find inherited changes in genes such as BRCA1, BRCA2, PALB2, ATM, or Lynch syndrome genes. The results may identify treatment options in certain advanced settings and help determine whether close relatives should discuss genetic counseling or screening.
What does KRAS wild-type mean in pancreatic cancer?
It means the test did not find a KRAS mutation in the tumor sample. Your oncology team may look for other driver changes or gene fusions, such as BRAF or NTRK, because some can be matched with targeted drugs.
Can BRCA or MSI-H results change pancreatic cancer treatment?
In some people with metastatic disease and a BRCA mutation whose cancer has not progressed after platinum chemotherapy, maintenance treatment with a PARP inhibitor such as olaparib may be considered. An MSI-H or dMMR tumor may be more likely to respond to immunotherapy when the cancer is unresectable or metastatic, but the result does not guarantee benefit.
What does a VUS mean on a genetic report?
A variant of uncertain significance is a DNA change whose effect is not known. It should not be used by itself to choose treatment, preventive surgery, or predictive testing for relatives.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my tumor conventional ductal adenocarcinoma (PDAC), acinar cell carcinoma (PACC), or a mixed type?
  2. 2.Does my pathology report follow a standardized 'synoptic' format including margin status and lymph node count?
  3. 3.If my biopsy was 'KRAS wild-type' (no KRAS mutation), what other driver mutations or fusions were found?
  4. 4.Can you explain the difference between my 'germline' genetic results and my 'somatic' tumor profiling?
  5. 5.Are there any 'variants of uncertain significance' (VUS) in my report that we should monitor as research evolves?
  6. 6.Based on my BRCA or MSI status, am I a candidate for targeted therapies like PARP inhibitors or immunotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Pancreatic Acinar Cell Carcinoma: A Rare Pancreatic Malignancy with Distinct Biology and Emerging Therapeutic Opportunities.

    Farhoud N, Al-Rajabi RMT, Baranda JC, et al.

    Cancers 2026; (18(14)) doi:10.3390/cancers18142315.

    PMID: 42512378
  2. 2

    Novel Insights Into Immunohistochemical Analysis For Acinar Cell Neoplasm of The Pancreas: Carboxypeptidase A2, Carboxypeptidase A1, and Glycoprotein 2.

    Ishimoto-Namiki U, Ino Y, Esaki M, et al.

    The American journal of surgical pathology 2023; (47(5)):525-534 doi:10.1097/PAS.0000000000002024.

    PMID: 36815573
  3. 3

    Pancreatic Cancer and Its Microenvironment-Recent Advances and Current Controversies.

    Stopa KB, Kusiak AA, Szopa MD, et al.

    International journal of molecular sciences 2020; (21(9)) doi:10.3390/ijms21093218.

    PMID: 32370075
  4. 4

    Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

    Singhi AD, George B, Greenbowe JR, et al.

    Gastroenterology 2019; (156(8)):2242-2253.e4 doi:10.1053/j.gastro.2019.02.037.

    PMID: 30836094
  5. 5

    Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features.

    Thompson ED, Wood LD

    Archives of pathology & laboratory medicine 2020; (144(7)):808-815 doi:10.5858/arpa.2019-0472-RA.

    PMID: 31869246
  6. 6

    Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.

    Mandelker D, Marra A, Zheng-Lin B, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(33)):5151-5162 doi:10.1200/JCO.23.00561.

    PMID: 37607324
  7. 7

    Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma.

    Blair AB, Radomski SN, Chou J, et al.

    Annals of surgical oncology 2025; (32(3)):1869-1878 doi:10.1245/s10434-024-16331-4.

    PMID: 39576455
  8. 8

    The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine.

    Bispo M, Marques S, Rio-Tinto R, et al.

    GE Portuguese journal of gastroenterology 2021; (28(2)):111-120 doi:10.1159/000509197.

    PMID: 33791398
  9. 9

    EUS-guided fine needle biopsy is able to provide diagnosis in rare osteoclast-like giant cells undifferentiated carcinoma of the pancreas: report of two cases.

    Pop RM, Diaconu CI, Rimbaş M, et al.

    Romanian journal of internal medicine = Revue roumaine de medecine interne 2023; (61(2)):116-124 doi:10.2478/rjim-2023-0008.

    PMID: 36884386
  10. 10

    Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomy specimens.

    Soer E, Brosens L, van de Vijver M, et al.

    Virchows Archiv : an international journal of pathology 2018; (472(4)):533-543 doi:10.1007/s00428-018-2321-5.

    PMID: 29589102
  11. 11

    Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry.

    Schuhbaur J, Surovtsova I, Seufferlein T, et al.

    BMC cancer 2024; (24(1)):1280 doi:10.1186/s12885-024-12995-z.

    PMID: 39407151
  12. 12

    International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer.

    van Roessel S, Kasumova GG, Verheij J, et al.

    JAMA surgery 2018; (153(12)):e183617 doi:10.1001/jamasurg.2018.3617.

    PMID: 30285076
  13. 13

    Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?

    He J, Blair AB, Groot VP, et al.

    Annals of surgery 2018; (268(1)):1-8 doi:10.1097/SLA.0000000000002672.

    PMID: 29334562
  14. 14

    An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.

    Rainone M, Singh I, Salo-Mullen EE, et al.

    JAMA oncology 2020; (6(5)):764-771 doi:10.1001/jamaoncol.2019.5963.

    PMID: 32053139
  15. 15

    Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.

    Brand R, Borazanci E, Speare V, et al.

    Cancer 2018; (124(17)):3520-3527 doi:10.1002/cncr.31628.

    PMID: 30067863
  16. 16

    The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.

    Mohindroo C, De Jesus-Acosta A, Yurgelun MB, et al.

    Surgical pathology clinics 2022; (15(3)):491-502 doi:10.1016/j.path.2022.05.004.

    PMID: 36049831
  17. 17

    Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.

    Emelyanova M, Pudova E, Khomich D, et al.

    Therapeutic advances in medical oncology 2022; (14()):17588359221083050 doi:10.1177/17588359221083050.

    PMID: 35309086
  18. 18

    Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.

    LaRose M, Manji GA, Bates SE

    Seminars in oncology 2024; (51(1-2)):36-44 doi:10.1053/j.seminoncol.2023.11.001.

    PMID: 38171988
  19. 19

    The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing.

    Walker EJ, Blanco AM, Carnevale J, et al.

    Pancreas 2022; (51(4)):302-304 doi:10.1097/MPA.0000000000002021.

    PMID: 35695740
  20. 20

    Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.

    Taïeb J, Sayah L, Heinrich K, et al.

    European journal of cancer (Oxford, England : 1990) 2023; (188()):90-97 doi:10.1016/j.ejca.2023.04.012.

    PMID: 37229836
  21. 21

    Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

    Hu ZI, Shia J, Stadler ZK, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2018; (24(6)):1326-1336 doi:10.1158/1078-0432.CCR-17-3099.

    PMID: 29367431
  22. 22

    Targeting DNA damage repair pathways in pancreas cancer.

    Crowley F, Park W, O'Reilly EM

    Cancer metastasis reviews 2021; (40(3)):891-908 doi:10.1007/s10555-021-09983-1.

    PMID: 34403012
  23. 23

    KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

    Krupa K, Fudalej M, Miski H, et al.

    Cancers 2025; (17(23)) doi:10.3390/cancers17233769.

    PMID: 41374970
  24. 24

    Dataset for the reporting of carcinoma of the exocrine pancreas: recommendations from the International Collaboration on Cancer Reporting (ICCR).

    Verbeke C, Webster F, Brosens L, et al.

    Histopathology 2021; (79(6)):902-912 doi:10.1111/his.14540.

    PMID: 34379823
  25. 25

    Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome.

    Matsubayashi H, Morizane C, Kanai M, et al.

    International journal of clinical oncology 2025; doi:10.1007/s10147-025-02905-z.

    PMID: 41118024
  26. 26

    Germline Mutations in DNA Repair Genes in Patients with Pancreatic Neuroendocrine Neoplasms: Diagnostic and Therapeutic Implications.

    Jurecka-Lubieniecka B, Ros-Mazurczyk M, Sygula A, et al.

    Current oncology (Toronto, Ont.) 2025; (32(11)) doi:10.3390/curroncol32110631.

    PMID: 41294693

This page explains pancreatic cancer pathology and genetic testing for informational purposes only and does not constitute medical advice. Ask your oncologist, pathologist, or genetic counselor to interpret your reports and treatment options.

Get notified when new evidence is published on exocrine pancreatic carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.